Sanofi Sees Dupixent As Just The Start Of COPD Transformation
Itepekimab Also In Development
Executive Summary
Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.